GRTX · As filed with the SEC
Galera Therapeutics balance sheet, by quarter
The statement as Galera Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS (unaudited) · USD
| USD | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 5,500,000 | 6,375,000 | 4,473,000 | 5,230,000 |
| Subscription receivable | — | 0 | 0 | 0 |
| Prepaid expenses and other current assets | 563,000 | 720,000 | 428,000 | 717,000 |
| Total current assets | 6,063,000 | 7,095,000 | 4,901,000 | 5,947,000 |
| Other assets | 101,000 | 101,000 | 101,000 | 101,000 |
| Total assets | 6,164,000 | 7,196,000 | 5,002,000 | 6,048,000 |
| Liabilities, redeemable convertible preferred stock and stockholders' deficit | ||||
| Current liabilities: | ||||
| Liabilities, Current | — | 645,000 | 598,000 | 347,000 |
| Royalty purchase liability | — | 0 | 151,049,000 | 151,049,000 |
| Warrant liability | — | 0 | 0 | 0 |
| Accounts payable | 699,000 | 265,000 | 434,000 | 202,000 |
| Accrued expenses | 442,000 | 380,000 | 164,000 | 145,000 |
| Liabilities | 1,141,000 | 645,000 | 151,647,000 | 151,396,000 |
| Stockholders' deficit: | ||||
| Series B Redeemable Convertible Preferred Stock | 4,295,000 | 2,577,000 | 2,577,000 | 2,597,000 |
| Common stock, $0.001 par value: 200,000,000 shares authorized; 75,462,390 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 75,000 | 75,000 | 75,000 | 75,000 |
| Additional paid-in capital | 309,573,000 | 311,213,000 | 311,121,000 | 311,010,000 |
| Accumulated deficit | (308,920,000) | (307,314,000) | (460,418,000) | (459,030,000) |
| Total stockholders' deficit | 728,000 | 3,974,000 | (149,222,000) | (147,945,000) |
| Total liabilities, redeemable convertible preferred stock and stockholders` equity | 6,164,000 | 7,196,000 | 5,002,000 | 6,048,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.